135 related articles for article (PubMed ID: 38130355)
1. Torsades de pointes due to oral sitafloxacin.
Wakayama Y; Yoshimura S; Hanabusa K; Ikeda N; Miyamae N; Sumida Y
Acute Med Surg; 2023; 10(1):e910. PubMed ID: 38130355
[No Abstract] [Full Text] [Related]
2. Efficacy and proarrhythmia with the use of d,l-sotalol for sustained ventricular tachyarrhythmias.
Kühlkamp V; Mermi J; Mewis C; Seipel L
J Cardiovasc Pharmacol; 1997 Mar; 29(3):373-81. PubMed ID: 9125676
[TBL] [Abstract][Full Text] [Related]
3. Baseline values and sotalol-induced changes of ventricular repolarization duration, heterogeneity, and instability in patients with a history of drug-induced torsades de pointes.
Couderc JP; Kaab S; Hinterseer M; McNitt S; Xia X; Fossa A; Beckmann BM; Polonsky S; Zareba W
J Clin Pharmacol; 2009 Jan; 49(1):6-16. PubMed ID: 18957528
[TBL] [Abstract][Full Text] [Related]
4. QT prolongation and Torsades de Pointes in patients previously treated with anthracyclines.
Arbel Y; Swartzon M; Justo D
Anticancer Drugs; 2007 Apr; 18(4):493-8. PubMed ID: 17351403
[TBL] [Abstract][Full Text] [Related]
5. K201, a multi-channel blocker, inhibits clofilium-induced torsades de pointes and attenuates an increase in repolarization.
Hasumi H; Matsuda R; Shimamoto K; Hata Y; Kaneko N
Eur J Pharmacol; 2007 Jan; 555(1):54-60. PubMed ID: 17112502
[TBL] [Abstract][Full Text] [Related]
6. The effect of intravenous haloperidol on QT interval dispersion in critically ill patients: comparison with QT interval prolongation for assessment of risk of Torsades de Pointes.
Tisdale JE; Rasty S; Padhi ID; Sharma ND; Rosman H
J Clin Pharmacol; 2001 Dec; 41(12):1310-8. PubMed ID: 11762558
[TBL] [Abstract][Full Text] [Related]
7. Female gender does not influence the magnitude of ibutilide-induced repolarization delay and incidence of torsades de pointes in an in vivo rabbit model of the acquired long QT syndrome.
Johansson M; Carlsson L
J Cardiovasc Pharmacol Ther; 2001 Jul; 6(3):247-54. PubMed ID: 11584331
[TBL] [Abstract][Full Text] [Related]
8. Drug-related torsades de pointes in the isolated rabbit heart: comparison of clofilium, d,l-sotalol, and erythromycin.
Eckardt L; Haverkamp W; Mertens H; Johna R; Clague JR; Borggrefe M; Breithardt G
J Cardiovasc Pharmacol; 1998 Sep; 32(3):425-34. PubMed ID: 9733356
[TBL] [Abstract][Full Text] [Related]
9. Rhythm anomalies related to delayed repolarization in vivo: influence of sarcolemmal Ca++ entry and intracellular Ca++ overload.
Carlsson L; Drews L; Duker G
J Pharmacol Exp Ther; 1996 Oct; 279(1):231-9. PubMed ID: 8858998
[TBL] [Abstract][Full Text] [Related]
10. Experimental models of torsades de pointes.
Weissenburger J; Davy JM; Chézalviel F
Fundam Clin Pharmacol; 1993; 7(1):29-38. PubMed ID: 8458600
[TBL] [Abstract][Full Text] [Related]
11. Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs.
Makkar RR; Fromm BS; Steinman RT; Meissner MD; Lehmann MH
JAMA; 1993 Dec; 270(21):2590-7. PubMed ID: 8230644
[TBL] [Abstract][Full Text] [Related]
12. Torsades de pointes associated with acquired long QT syndrome: observation of 7 cases.
Takahashi N; Ito M; Inoue T; Koumatsu K; Takeshita Y; Tsumabuki S; Tamura M; Inoue K; Maeda T; Saikawa T
J Cardiol; 1993; 23(1):99-106. PubMed ID: 8164140
[TBL] [Abstract][Full Text] [Related]
13. Monophasic action potentials in patients with torsades de pointes.
Miwa S; Inoue T; Yokoyama M
Jpn Circ J; 1994 Apr; 58(4):248-58. PubMed ID: 8051783
[TBL] [Abstract][Full Text] [Related]
14. Amiodarone and torsades de pointes in patients with advanced heart failure.
Middlekauff HR; Stevenson WG; Saxon LA; Stevenson LW
Am J Cardiol; 1995 Sep; 76(7):499-502. PubMed ID: 7653452
[TBL] [Abstract][Full Text] [Related]
15. Torsades de pointes: arrhythmia, syndrome, or chimera? A perspective in the light of the Lambeth Conventions.
Curtis MJ
Cardiovasc Drugs Ther; 1991 Feb; 5(1):191-200. PubMed ID: 2036339
[TBL] [Abstract][Full Text] [Related]
16. Adenosine induced torsades de pointes in a child with congenital long QT syndrome.
Celiker A; Tokel K; Cil E; Ozkutlu S; Ozme S
Pacing Clin Electrophysiol; 1994 Nov; 17(11 Pt 1):1814-7. PubMed ID: 7838793
[TBL] [Abstract][Full Text] [Related]
17. Torsades de pointes associated with fluoroquinolones: importance of concomitant risk factors.
Amankwa K; Krishnan SC; Tisdale JE
Clin Pharmacol Ther; 2004 Mar; 75(3):242-7. PubMed ID: 15001976
[TBL] [Abstract][Full Text] [Related]
18. A Rare Presentation of Levetiracetam-Induced Torsades De Pointes.
Mann H; Kusayev J; Pandey S; Aryal B; Solaimanzadeh I
Cureus; 2023 Jun; 15(6):e40866. PubMed ID: 37492848
[TBL] [Abstract][Full Text] [Related]
19. Torsades de pointes associated with chlorpromazine: case report and review of associated ventricular arrhythmias.
Hoehns JD; Stanford RH; Geraets DR; Skelly KS; Lee HC; Gaul BL
Pharmacotherapy; 2001 Jul; 21(7):871-83. PubMed ID: 11444585
[TBL] [Abstract][Full Text] [Related]
20. A canine model of torsades de pointes.
Leichter D; Danilo P; Boyden P; Rosen TS; Rosen MR
Pacing Clin Electrophysiol; 1988 Dec; 11(12):2235-45. PubMed ID: 2463611
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
